Anakinra and canakinumab, monoclonal antibodies that target IL-1β, have been used to reduce SAA levels in inflammatory conditions such as Familial Mediterranean Fever (300) and gouty arthritis (301). The gene discussed is SAA2; the disease is familial Mediterranean fever.